Plain-English translation of NCT07192211 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether ADR-002K, a type of stem cell derived from fat tissue, can help hearts recover after bypass surgery in patients with severe heart damage. The stem cells are applied directly to the surface of the heart during surgery. Researchers will follow participants for 2 years to see if this treatment improves heart function and is safe.
Many people who have bypass surgery still have weak heart function afterward, which limits their activity and quality of life. This medication may help the heart repair itself and work better after surgery.
You likely qualify if…
You likely don't qualify if…
You will undergo bypass surgery as you normally would, but during surgery the research team will apply stem cells to your heart's surface — half of participants receive the active treatment and half receive a placebo (inactive treatment), and neither you nor your doctors will know which you received. You will then have follow-up appointments over 2 years where your heart function is checked with imaging and blood tests to see how well the treatment worked.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Japan
Testing effectiveness
Sponsor
Rohto Pharmaceutical Co., Ltd.
Enrollment target
~50 participants
Started
April 2026
Primary completion
September 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sumito Okawa, Study Director
Osaka University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.